Strategies for improving the clinical benefit of antiangiogenic drug based therapies for breast cancer.
about
Antiangiogenesis therapy for breast cancer: an update and perspectives from clinical trialsMeroxest improves the prognosis of immunocompetent C57BL/6 mice with allografts of E0771 mouse breast tumor cells.Lymphovascular and neural regulation of metastasis: shared tumour signalling pathways and novel therapeutic approaches.What is known about melatonin, chemotherapy and altered gene expression in breast cancerDifferential expression of VEGFR2 protein in HER2 positive primary human breast cancer: potential relevance to anti-angiogenic therapies.Anandamide inhibits breast tumor-induced angiogenesisAnalysis of acquired resistance to metronomic oral topotecan chemotherapy plus pazopanib after prolonged preclinical potent responsiveness in advanced ovarian cancer.Modulation of murine breast tumor vascularity, hypoxia and chemotherapeutic response by exercise.The pharmacological bases of the antiangiogenic activity of paclitaxel.Metronomic chemotherapy: possible clinical application in advanced hepatocellular carcinomaCritical research gaps and translational priorities for the successful prevention and treatment of breast cancer.Vandetanib as a potential treatment for breast cancer.Novel antiangiogenic drugs for the management of breast cancer: new approaches for an old issue?Preclinical analysis of resistance and cross-resistance to low-dose metronomic chemotherapy.Antiangiogenesis and vascular disrupting agents in cancer: circumventing resistance and augmenting their therapeutic utility.A novel vaccinia virus with dual oncolytic and anti-angiogenic therapeutic effects against triple-negative breast cancer.Loss of WAVE3 sensitizes triple-negative breast cancers to chemotherapeutics by inhibiting the STAT-HIF-1α-mediated angiogenesis.Monitoring vascular normalization induced by antiangiogenic treatment with (18)F-fluoromisonidazole-PET.Role of vascular normalization in benefit from metronomic chemotherapy.Disrupting Tumor Angiogenesis and "the Hunger Games" for Breast Cancer.Combination of anti-angiogenic therapies reduces osteolysis and tumor burden in experimental breast cancer bone metastasis
P2860
Q26822432-D1ACB5B0-CD9D-4184-B7D4-3146C4EDCBEDQ31134354-F5963289-C84B-4E3D-9687-308DC35BAEB9Q33555154-112CBFB9-E43B-4917-A28D-B17D1DF7A283Q33597963-8766DD4F-A56B-434D-A73B-15CB7980BC7CQ33709284-09032F32-482D-4CEE-B0AB-0AD06ACF8295Q34074335-1B5F5E86-8263-42E6-A5C0-6FAB904CB57DQ35966821-B8BEC8FA-34BF-4A8F-B65A-5B6C53C20512Q36770262-185A40AE-984E-420C-885C-8FDA8C908CC4Q36927558-1C0F9528-2C64-41F3-9799-7210CEE90CB3Q37236004-64356B4B-9200-4E66-B3B9-0D3EDD5B9C66Q37533025-74BC1D8B-E07B-4C94-B590-A8761A07077EQ38236623-6AC5F496-F077-410B-8E17-CDE4C41C3462Q38322346-6672F6A8-05BA-4D51-B9C6-E21777A5CC03Q38489591-9CB50E47-1CDD-41BB-8849-E73FF87AE645Q38757723-08E0C744-A3BF-4589-9527-FA80052B9055Q38940868-8A0DAA5D-52F6-44EB-8D65-6B817DBE3B37Q40492761-EF9FA776-6502-48FE-9657-942C2DA1B6ECQ42282877-2ABC1C47-0FFD-459F-A01B-AFC554BDCA9AQ42318133-F4DEE0CB-1043-493C-8FD6-6C7B58003291Q49544357-BA005204-E9DC-495B-94F9-9D350EA3795AQ58217157-1460D9D7-B82F-45F4-B9BB-DF94712C3F04
P2860
Strategies for improving the clinical benefit of antiangiogenic drug based therapies for breast cancer.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Strategies for improving the c ...... d therapies for breast cancer.
@en
type
label
Strategies for improving the c ...... d therapies for breast cancer.
@en
prefLabel
Strategies for improving the c ...... d therapies for breast cancer.
@en
P2860
P1476
Strategies for improving the c ...... d therapies for breast cancer.
@en
P2093
Robert S Kerbel
P2860
P2888
P304
P356
10.1007/S10911-012-9266-0
P577
2012-09-26T00:00:00Z